Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 1-6

  Ni, Qinggui ^a,b   Ji, Hui ^a   Zhao, Zhihui ^c   Fan, Xin ^b   Xu, Chengyun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Simcere Pharmaceutical Research Institute   (China)

^c NANJING NORMAL UNIVERSITY   (China)

Author keywords

V 3 integrin; CD44v6; Endostar; In vitro invasion; Matrix metalloproteinase; Non small cell lung cancer; Osteopontin

Indexed keywords

CD44V6 ANTIGEN; ENDOSTAR; ENDOSTATIN; GELATINASE A; GELATINASE B; OSTEOPONTIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CULTURE MEDIA; DOWN-REGULATION; ENDOSTATINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; METALLOPROTEASES; OSTEOPONTIN;

EID: 67349222087     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.032     Document Type: Article

References (36)

1. Abraham D., Abri S., Hofmann M., Holtl W., and Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J. Urol. 170 (2003) 1388-1393
2. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., and Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. 94 (2002) 513-521
3. Bayless K.J., Meininger G.A., Scholtz J.M., and Davis G.E. Osteopontin is a ligand for the alpha 4 beta1 integrin. J. Cell Sci. 111 (1998) 1165-1174
4. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
5. Calvo A., Yokoyama Y., Smith L.E., Ali I., Shih S.C., Feldman A.L., Libutti S.K., Sundaram R., and Green J.E. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int. J. Cancer 101 (2002) 224-234
6. Chambers A.F., Wilson S.M., Kerkvliet N., Omalley F.P., Harris J.F., and Casson A.G. Osteopontin expression in lung cancer. Lung Cancer 15 (1996) 311-323
7. Coussens L.M., and Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Biol. 3 (1996) 895-904
8. Denda S., Reichardt L.F., and Muller U. Identification of osteopontin as a novel ligand for the integrin alpha 8 beta 1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol. Biol. Cell 9 (1998) 1425-1435
9. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., and Sukhatme V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274 (1999) 11721-1176
10. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., and Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 7 (2001) 4060-4066
11. Han Y.P., Tuan T.L., Wu H., Hughes M., and Garner W.L. TNF alpha stimulates activation of pro MMP-2 in human skin through NF(kappa) B mediated induction of MT1 MMP. J. Cell Sci. 114 (2001) 131-139
12. Hruska K.A., Rolnick F., Huskey M., Alvarez U., and Cheresh D. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology 136 (1995) 2984-2992
13. 2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin alpha v beta 3. J. Biol. Chem. 270 (1995) 9917-9925
14. Khodavirdi A.C., Song Z.G., Yang S.X., Zhong C., Wang S.Y., Wu H., Pritchard C., Nelson P.S., and Pradip R.B. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 66 (2006) 883-888
15. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., Lee S.T., and Kwon Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60 (2000) 5410-5413
16. O'Reilly M.S., Boehm T., Shin Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 8 (1997) 277-285
17. Pan H.W., Ou Y.H., Peng S.Y., Liu S.H., Lai P.L., Lee P.H., Sheu J.C., Chen C.L., and Hsu H.C. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98 (2003) 119-127
18. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., Mukherjee B.B., Li X.D., Mukherjee D.C., Seides S., Ros enberg J., Stark K., and Mukherjee A.B. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. 94 (1997) 9308-9313
19. Philip S., and Kundu G.C. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (Diferulolylmethane) carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J. Hepatol. 32 (2000) 78-84
20. Philip S., and Kundu G.C. Osteopontin induces nuclear factor-kappa-B-mediated promatrix metalloproteinase-2 activation through IkB alpha/IKK signaling pathways and curcumin (Diferulolylmethane) down regulates these pathways. J. Biol. Chem. 278 (2003) 14487-14497
21. Philip S., Bulbule A., and Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-Kappa-B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma Cells. J. Biol. Chem. 276 (2001) 44926-44935
22. Ponta H., Sherman L., and Herrlich P.A. CD44:from adhesion molecules to signalling regulators. Nat. Rev., Mol. Cell Biol. 4 (2003) 33-45
23. Rangaswami H., Bulbule A., and Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16 (2006) 79-87
24. Senger D.R., Perruzzi C.A., Gracey C.F., Papadopoulos A., and Tenen D.G. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 48 (1988) 5770-5774
25. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos S.A., Peruzzi C.A., and Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alpha v beta 3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149 (1996) 293-305
26. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., Hirasawa M., and Abe S. Vascular endothelial growth factor andosteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160 (1999) 1269-1273
27. Smith L.L., Cheung H.K., Ling L.E., Chen J., Sheppard D., Pytela R., and Giachelli C.M. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha 9 beta 1 integrin. J. Biol. Chem. 271 (1996) 28485-28491
28. Sodek J., Ganss B., and McKee M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 11 (2000) 279-303
29. Standal T., Hjorth-Hansen H., Rasmussen T., Dahl I.M., Lenhoff S., Brenne A.T., Seidel C., Baykov V., Waage A., Borset M., Sundan A., and Hjertner O. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 89 (2004) 174-182
30. Takano S., Tsuboi K., Tomono Y., Mitsui Y., and Nose T. Tissue factor, osteopontin, alpha v beta 3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer 82 (2000) 1967-1973
31. Te Velde E.A., Reijerkerk A., and Brandsma D. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br. J. Cancer 92 (2005) 729-735
32. Tuck A.B., O'malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., and Chambers A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 79 (1998) 502-508
33. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., and Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer 79 (1998) 127-132
34. Xia H., Luo L.M., Fan Y.F., Tong W.C., and Wen J.X. Inhibitory effect of recombinant human endostatin on angiogenesis and lung metastasis of mouse lung adenocarcinoma. LA795. Journal of First Military Medical University 23 (2003) 30-33
35. Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., Que I., Lowik C.T., and Olsen B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18 (1999) 4414-4123
36. Yao H.C., Jin D.J., Sun Y.N., Ren M.H., and Li X.D. Endostatin in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice. Chinese Journal of Otorhinolaryngology Head and Neck Surgery 39 (2004) 394-398